PORTOSPLENOMESENTERIC VENOUS THROMBOSIS

PORTOSPLENOMESENTERIC VENOUS THROMBOSIS was reported 61 times

PORTOSPLENOMESENTERIC VENOUS THROMBOSIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Human Blood Coagulation Factor [EPC] 1 0.0012
1 Thrombopoietin Receptor Agonist [EPC] 2 0.0001
2 Androgen [EPC] 2 0.0001
3 Cholinesterase Inhibitor [EPC] 1 0.0001
4 Janus Kinase Inhibitor [EPC] 8 0.0000
5 Human Immunoglobulin G [EPC] 1 0.0000
6 Aluminum Complex [EPC] 1 0.0000
7 Programmed Death Receptor-1 Blocking Antibody [EPC] 4 0.0000
8 Provitamin D2 Compound [EPC] 1 0.0000
9 Dipeptidyl Peptidase 4 Inhibitor [EPC] 1 0.0000
10 Microtubule Inhibitor [EPC] 4 0.0000
11 Nucleoside Analog Antiviral [EPC] 2 0.0000
12 Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] 1 0.0000
13 Platinum-based Drug [EPC] 5 0.0000
14 Complement Inhibitor [EPC] 1 0.0000
15 Vascular Endothelial Growth Factor Inhibitor [EPC] 2 0.0000
16 Estrogen [EPC] 2 0.0000
17 Interleukin-23 Antagonist [EPC] 1 0.0000
18 Folate Analog Metabolic Inhibitor [EPC] 4 0.0000
19 Aromatase Inhibitor [EPC] 1 0.0000
20 Nucleoside Metabolic Inhibitor [EPC] 2 0.0000
21 Factor Xa Inhibitor [EPC] 2 0.0000
22 Interleukin-6 Receptor Antagonist [EPC] 1 0.0000
23 Progestin [EPC] 2 0.0000
24 Vitamin D [EPC] 2 0.0000
25 Vitamin B12 [EPC] 2 0.0000
26 Vitamin C [EPC] 2 0.0000
27 Tumor Necrosis Factor Blocker [EPC] 4 0.0000
28 CD20-directed Cytolytic Antibody [EPC] 1 0.0000
29 Corticosteroid [EPC] 4 0.0000
30 HMG-CoA Reductase Inhibitor [EPC] 1 0.0000
31 Nonsteroidal Anti-inflammatory Drug [EPC] 3 0.0000
32 GLP-1 Receptor Agonist [EPC] 1 0.0000
33 Thalidomide Analog [EPC] 1 0.0000
34 Platelet Aggregation Inhibitor [EPC] 1 0.0000
35 Proton Pump Inhibitor [EPC] 1 0.0000
36 Benzodiazepine [EPC] 1 0.0000